BioLineRx of Israel and I-Bridge Capital Form China JV for Drug In-licensing

BioLineRx, an Israeli in-licensing company, established a joint venture with I-Bridge Capital, a China VC investor seeking to develop innovative therapies for China. The JV, named iPharma, will look primarily in Israel to license innovative clinical and pre-clinical candidates for China and international markets. BioLineRx has already out-licensed two of its candidates to China companies; it isn't clear if the JV will be BioLineRx's agent in China for additional deals. Each company will invest $1 million in the JV initially. More details.... Stock Symbols: (NSDQ/TASE: BLRX) Share this with colleagues: // //